As an embodiment of the present invention, the reagent used for controlling the reaction pH in step (1) is a solution composed of a base, water and an organic solvent, the base is selected from an organic base or an inorganic base, the organic base is selected from any one of triethylamine, N-diisopropylethylamine, pyridine, piperidine and aniline, the inorganic base is selected from any one of alkali metal hydroxide and alkali metal carbonate, such as any one of sodium hydroxide, potassium hydroxide, sodium hydrogen phosphate and potassium hydrogen phosphate
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1
Compounding semaglutide allows personalized formulations for patients that are not commercially available
For pharma, the race is now on to ramp up and optimise production while developing the next generation of these drugs
Semaglutide is a drug used to treat type 2 diabetes and sometimes to help tackle obesity
"Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss"